摘要
目的 探讨检验粪便中双歧杆菌、大肠杆菌水平对于肝癌预后效果的评估作用。方法 选取2020年1月—2021年2月在该院就诊的44例肝癌患者作为观察组,另选取在该院接受体检的44名健康者作为对照组,对两组粪便中的双歧杆菌与大肠杆菌含量进行检测,同时分析肝癌患者中死亡组与存活组的血液学指标、双歧杆菌与大肠杆菌含量之间的比值等。结果 观察组双歧杆菌水平为(5.08±0.61)×10^(9)/L,较对照组的(6.94±0.85)×10^(9)/L低,大肠杆菌水平为(8.73±2.66)×10^(9)/L,较对照组的(7.25±2.27)×10^(9)/L高,观察组两者比值为(0.58±0.23),较对照组的(0.96±0.37)低,差异有统计学意义(P<0.05)。肝癌患者中死亡组与存活组的AFP分别为(153.29±15.28)、(108.44±13.61)ng/mL;PLT分别为(177.36±18.62)×10^(9)/L、(135.82±13.64)×10^(9)/L;WBC分别为(25.37±4.36)×10^(9)/L、(17.83±1.59)×10^(9)/L;ALT分别为(36.85±3.43)、(25.86±3.15)U/L;AST分别为(33.61±3.29)、(23.37±3.04)U/L;TBIL分别为(24.67±3.14)、(16.28±2.12)μmol/L,差异有统计学意义(t=14.539、11.938、10.777、15.654、15.163、14.689,P<0.05)。肝癌患者中死亡组的双歧杆菌水平明显低于存活组,大肠杆菌水平明显高于存活组,双歧杆菌/大肠杆菌明显低于存活组,差异有统计学意义(t=13.505、2.883、4.269,P<0.001)。结论 对肝癌患者粪便中的双歧杆菌、大肠杆菌水平进行检验,能够为其预后提供依据。
Objective To investigate the effect of detecting the levels of Bifidobacterium and Escherichia coli in feces in evaluating the prognosis of hepatocellular carcinoma.Methods From January 2020 to February 2021,44 patients with liver cancer who were treated in the hospital were selected as the observation group,and 44 healthy people who received physical examination in the hospital were selected as the control group.The contents of bifidobacteria and Escherichia coli in the feces of the two groups were detected.At the same time,the hematological indexes,the ratio between the content of bifidobacteria and Escherichia coli in the death group and the survival group were analyzed.Results The level of bifidobacteria in the observation group was(5.08±0.61)×10^(9)/L,which was lower than that of the control group(6.94±0.85)×10^(9)/L;the level of Escherichia coli was(8.73±2.66)×10^(9)/L,which was lower than that of the control group(7.25±2.27)×10^(9)/L;the ratio between the two in the observation group was(0.58±0.23),which was lower than that in the control group(0.96±0.37),the difference was statistically significant(P<0.05).In liver cancer patients,the AFP of the death group and the survival group were(153.29±15.28) ng/mL,(108.44±13.61) ng/mL;PLT were(177.36 ±18.62) ×10^(9)/L,(135.82 ±13.64) ×10^(9)/L;WBC were(25.37 ±4.36) ×10^(9)/L,(17.83 ±1.59) ×10^(9)/L;ALT were(36.85±3.43) U/L,(25.86±3.15) U/L;AST were(33.61±3.29) U/L,(23.37±3.04) U/L;TBIL were(24.67±3.14) μmol/L,(16.28±2.12) μmol/L,the difference was statistically significant(t=14.539,11.938,10.777,15.654,15.163,14.689,P<0.05).In liver cancer patients,the level of Bifidobacterium in the death group was significantly lower than that in the survival group;the level of Escherichia coli was significantly higher than that in the survival group;Bifidobacterium/Escherichia coli was significantly lower than the survival group,and the difference was statistically significant(t =13.505,2.883,4.269,P <0.001).Conclusion Testing the levels of Bifidobact
作者
杨芬莲
温海鹏
成江燕
梁丽仪
YANG Fenlian;WEN Haipeng;CHENG Jiangyan;LIANG Liyi(Department of Laboratory Medicine,People's Hospital of Gaoming District,Foshan,Guangdong Province,528500 China)
出处
《系统医学》
2022年第5期83-86,共4页
Systems Medicine
关键词
双歧杆菌
大肠杆菌
肝癌
检验
预后效果
Bifidobacteria
Escherichia coli
Liver cancer
Test
Prognostic effect
